GLPwatch
Papers (12034)
Page 147 of 201, ranked by citation count.
- Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1).
- Dulaglutide and pregnancy: a comprehensive safety assessment using the <i>ex vivo</i> placenta perfusion and <i>in vitro</i> models.
- Dual-phase exenatide delivery system: PLGA nanoparticles embedded in thermosensitive PLGA-PEG-PLGA hydrogel for sustained glycemic control.
- Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
- Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review.
- Impact of glucagon-like peptide-1 receptor agonists on the incidence of atrial fibrillation.
- Liraglutide as a novel therapeutic for overweight in canines: A clinical study.
- Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes.
- Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats.
- PIONEER REAL Saudi Arabia: A multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia.
- Enhanced Transdermal Delivery of Liraglutide for Sustained Obesity Management.
- GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.
- DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
- [Incretin therapy and the metabolic syndrome].
- Glucagon-Like Peptide-1 Receptor Agonists Combined With Personalized Digital Health Care for the Treatment of Metabolic Syndrome in Adults With Obesity: Retrospective Observational Study.
- Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with Type 2 diabetes.
- Semaglutide in Heart Failure: A Systematic Review of Outcomes of Semaglutide in Heart Failure Patients.
- Liraglutide in type 2 diabetes mellitus.
- Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.
- Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.
- Sex-specific changes in GLP-1RA trends (2019-2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States.
- Drugs and devices for weight management.
- Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats.
- SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.
- Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.
- Safe use of a once-a-week glucagon-like peptide-1 receptor agonist in a 16-year-old girl with type 2 diabetes when approved therapy options fail.
- [Changes in weight, body composition, metabolic parameters and vitamin D in subjects with grade 3 and 4 obesity treated with liraglutide 3 mg].
- Effect of New Antidiabetics on Steatosis in Nerve Tissues and Nerve Conduction Velocity: Possible Role of Nerve Growth Factor (NGF)/Synaptophysin and Nrf2/HO-1 Pathways.
- Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
- Analysis of semaglutide's effect on Alzheimer's disease risk.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- Weekly Journal Scan: improved renal outcomes by semaglutide in patients with chronic kidney disease and type 2 diabetes in FLOW trial.
- Opaganib Promotes Weight Loss and Suppresses High-Fat Diet-Induced Obesity and Glucose Intolerance.
- Liraglutide: another reason to target prediabetes?
- [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
- Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.
- Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.
- Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs.
- Characterizing the D-Amino Acid Position in Peptide Epimers by Using Higher-Energy Collisional Dissociation Tandem Mass Spectrometry: A Case Study of Liraglutide.
- Bariatric surgery vs. GLP-1 receptor agonists among primarily medicare and medicaid patients with diabetes: a 3-year analysis.
- Proglucagon-Derived Peptides Do Not Significantly Affect Acute Exocrine Pancreas in Rats.
- [Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes].
- A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss.
- Reduced 90-Day Cardiovascular and Infectious Complications After Open Reduction Internal Fixation of Ankle Fractures in Type II Diabetic Patients Using Semaglutide Preoperatively.
- Semaglutide Inducing Resolution of Proliferative Diabetic Retinopathy: A Case Report.
- Switching from insulin injections to degludec/liraglutide in older frail persons: 6-month body composition remodelling.
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.
- Clinical Potential of GIP in Type 2 Diabetes and Obesity.
- Effects of Liraglutide on Mitigation of Hearing Loss After Repeated Blast Exposures: A Summary of Studies in Animal Model of Chinchilla.
- Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies.
- More on Semaglutide in Early Type 1 Diabetes.
- Cardiovascular Outcomes Trials of Incretin-Based Therapies.
- Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
- Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
- The global transcriptional response of isolated human islets of langerhans to glucagon-like Peptide-1 receptor agonist liraglutide.
- Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides.
- The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics.
- In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.
- Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.